Comparative Pharmacology
Head-to-head clinical analysis: COMPAZINE versus VONTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COMPAZINE versus VONTROL.
COMPAZINE vs VONTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dopamine D2 receptor antagonist in the chemoreceptor trigger zone; also blocks alpha-1 adrenergic, histamine H1, and muscarinic M1 receptors.
VONTROL (trimethobenzamide) acts centrally to inhibit the chemoreceptor trigger zone (CTZ) in the medulla oblongata, thereby suppressing nausea and vomiting. Its exact mechanism is not fully understood but may involve antagonism of dopamine D2 receptors and serotonin 5-HT3 receptors.
5-10 mg IM/IV every 3-4 hours as needed; or 25 mg PO/PR twice daily for severe nausea/vomiting.
10 mg orally twice daily; maximum 20 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 23 hours (range 15-30 hours) after oral or intramuscular administration. Clinical context: requires multiple daily dosing for steady state.
12 hours; prolonged in renal impairment (up to 24 hours in ESRD)
Renal (approximately 70% as metabolites, <1% unchanged), biliary/fecal (approximately 30%).
Renal: 60% unchanged; fecal: 30% (biliary); hepatic metabolism: 10%
Category C
Category C
Antipsychotic (Phenothiazine) / Antiemetic
Antiemetic